Shao-Hsi Hung

Shao-Hsi Hung

Auto-generated profile, based on publicly available information

Shao-Hsi Hung

Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 115201, Taiwan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Cancer Letters
Verified
Journal Article
Closed access
KLKang-Hao Liang
Kang-Hao Liang
HTHsien-Cheng Tso
Hsien-Cheng Tso
SHShao-Hsi Hung
Shao-Hsi Hung
IKI.-I. Kuan
I.-I. Kuan
JLJun-Kai Lai
Jun-Kai Lai
HWHan-Chung Wu
Han-Chung Wu

10 July 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
MZMingjie Zheng
Mingjie Zheng
JJJoan Jacob
Joan Jacob
SHShao-Hsi Hung
Shao-Hsi Hung
Jun WangJun Wang
Jun Wang
Intractable cardiovascular diseases are leading causes of mortality around the world. Adult mammalian hearts have poor regenerative capacity and are not capable of self-repair after injury. Recent studies of cell-free therapeutics such as those designed to stimulate endogenous cardiac regeneration have uncovered new feasible therapeutic avenues for cardiac repair. The Hippo pathway, a fundamental pathway with pivotal roles in cell proliferation, survival and differentiation, has tremendous potential for therapeutic manipulation in cardiac regeneration. In this review, we summarize the most recent studies that have revealed the function of the Hippo pathway in heart regeneration and homeostasis. In particular, we discuss the molecular mechanisms of how the Hippo pathway maintains cardiac homeostasis by directing cardiomyocyte chromatin remodeling and regulating the cell-cell communication between cardiomyocytes and non-cardiomyocytes in the heart.

4 March 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
TGTorahito A. Gao
Torahito A. Gao
RSRyan M. Shih
Ryan M. Shih
JCJustin D. Clubb
Justin D. Clubb
SHShao-Hsi Hung
Shao-Hsi Hung
TSTanya Singh
Tanya Singh
YCYvonne Y. Chen
Yvonne Y. Chen
Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy against solid tumors, which often reside in highly immunosuppressive tumor microenvironments (TMEs). TMEs can be highly abundant in vascular endothelial growth factor A (VEGF), which contributes to immunosuppression and abnormal tumor vasculature. Here, we found that CAR T cells engineered to secrete an anti-VEGF single-chain variable fragment (CAR-αVEGF T cells) achieved superior antitumor efficacy against multiple in vivo models of ovarian cancer and glioma, outperforming conventional CAR T cells with and without combination anti-VEGF antibody therapy. Microscopy, flow cytometry, and transcriptomic analyses revealed that armoring the CAR T cells with anti-VEGF single-chain variable fragments enhanced their activation and mitochondrial fitness and enriched immune-stimulatory signatures among endogenous immune cells in the tumor-bearing brain. Moreover, CAR-αVEGF T cells circumvented multiple detrimental effects associated with on-target CAR T cell therapy, including infiltration of suppressive myeloid cells, exaggerated vasculature abnormalities, and hypoxia. Together, our results provide rationale for the clinical translation of CAR-αVEGF T cells as a safe and potent therapy for solid tumors characterized by elevated VEGF.